X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (270) 270
Publication (45) 45
Patent (30) 30
Book Review (4) 4
Web Resource (4) 4
Book / eBook (3) 3
Conference Proceeding (2) 2
Technical Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (127) 127
oncology (109) 109
index medicus (94) 94
lung neoplasms - drug therapy (81) 81
carcinoma, non-small-cell lung - drug therapy (72) 72
female (64) 64
male (63) 63
aged (62) 62
middle aged (58) 58
lung neoplasms - genetics (56) 56
lung neoplasms - pathology (54) 54
chemotherapy (52) 52
mutation (49) 49
carcinoma, non-small-cell lung - genetics (48) 48
lung cancer (47) 47
antineoplastic agents - therapeutic use (46) 46
adult (44) 44
carcinoma, non-small-cell lung - pathology (42) 42
gefitinib (42) 42
receptor, epidermal growth factor - genetics (40) 40
lung cancer, non-small cell (37) 37
cancer (35) 35
erlotinib (35) 35
respiratory system (35) 35
protein kinase inhibitors - therapeutic use (34) 34
non-small cell lung cancer (33) 33
egfr (31) 31
open-label (31) 31
beer (30) 30
biochemistry (30) 30
chemistry (30) 30
compositions or test papers therefor (30) 30
condition-responsive control in microbiological orenzymological processes (30) 30
enzymology (30) 30
measuring or testing processes involving enzymes, nucleicacids or microorganisms (30) 30
metallurgy (30) 30
microbiology (30) 30
mutation or genetic engineering (30) 30
processes of preparing such compositions (30) 30
spirits (30) 30
vinegar (30) 30
wine (30) 30
quinazolines - therapeutic use (29) 29
aged, 80 and over (27) 27
tyrosine kinase inhibitors (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
nsclc (25) 25
care and treatment (24) 24
prognosis (24) 24
treatment outcome (24) 24
acquired-resistance (23) 23
receptor, epidermal growth factor - antagonists & inhibitors (23) 23
research (23) 23
1st-line treatment (22) 22
hematology, oncology and palliative medicine (21) 21
neoplasm staging (21) 21
phase-iii trial (20) 20
growth-factor receptor (19) 19
lung neoplasms - metabolism (19) 19
carcinoma, non-small-cell lung - mortality (18) 18
cell lung-cancer (18) 18
derivatives thereof (18) 18
disease progression (18) 18
gene copy number (18) 18
lung neoplasms - mortality (18) 18
nucleic acids (18) 18
nucleosides (18) 18
nucleotides (18) 18
organic chemistry (18) 18
sugars (18) 18
tyrosine kinase inhibitor (18) 18
adenocarcinoma (17) 17
carcinoma, non-small-cell lung - metabolism (17) 17
egfr mutations (17) 17
growth-factor-receptor (17) 17
in situ hybridization, fluorescence (17) 17
survival (17) 17
survival analysis (17) 17
tumors (17) 17
antineoplastic agents - pharmacology (16) 16
disease-free survival (16) 16
docetaxel (16) 16
drug resistance, neoplasm (16) 16
non-small-cell lung cancer (16) 16
therapy (16) 16
animals (15) 15
clinical trials as topic (15) 15
metastasis (15) 15
pulmonary/respiratory (15) 15
cetuximab (14) 14
drug therapy (14) 14
epidermal growth factor (14) 14
molecular targeted therapy (14) 14
patients (14) 14
phase-ii trial (14) 14
respiratory tract diseases (14) 14
analysis (13) 13
clinical trials (13) 13
immunohistochemistry (13) 13
pharmacology & pharmacy (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2015, 1st ed. 2015., ISBN 3319207415
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current... 
Medicine | Oncology
Web Resource
2015, 1st ed. 2015., ISBN 3319207415
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current... 
Medicine | Oncology
Web Resource
2014, ISBN 9783319030586
Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current... 
Medicine | Oncology | Pneumology
Web Resource
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2019, Volume 20, Issue 9, pp. e467 - e467
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 6, pp. 521 - 529
Journal Article
2015, 1st ed. 2015, ISBN 3319207407, 71
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current... 
Clinical & internal medicine | Oncology | Medicine & Public Health
eBook
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Journal Article
Drugs, ISSN 0012-6667, 06/2012, Volume 72, Issue 9, p. S1
Journal Article
Drugs, ISSN 0012-6667, 06/2012, Volume 72, Issue suppl_1 Management, p. 1
Journal Article
Drugs, ISSN 0012-6667, 06/2012, Volume 72, pp. 1 - 2
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S177 - S178
Journal Article
Drugs, ISSN 0012-6667, 1/2012, Volume 72, Issue S1, pp. 1 - 2
Journal Article
Drugs, ISSN 0012-6667, 2012, Volume 72, Issue 1, pp. 1 - 2
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2018, Volume 24, Issue 11, pp. 2470 - 2472
HER2-deregulated non-small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective... 
RESISTANCE | ONCOLOGY | GEFITINIB THERAPY | GENE COPY NUMBER | MUTATION | Acrylamides | Piperazines | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Aniline Compounds | Humans | Deregulation | ErbB-2 protein | Lung cancer | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article